**Obraz zawierający tekst, zrzut ekranu, projekt graficzny, miejsce parkingowe/przestrzeń

Zawartość wygenerowana przez sztuczną inteligencję może być niepoprawna.**

**How Far Are We from WHO HCV Elimination 2030 Goals with 10 Years of Revolutionary Treatments?**  
**Conference of Polish Hepatology Experts' Group**

**25.04.2025**

**12.00 – 13.40 I OPENING SESSION**

* **12.00 – 12.10**  
  Opening and Introduction – **Prof. Krzysztof Tomasiewicz**, Head of HCV Polish Experts Group
* **12.10 – 12.20**  
  Polish Perspective towards HCV Elimination, Polish Presidency in EU - **Izabela Leszczyna**, Polish Ministry of Health
* **12.20 - 12.30**  
  Strategic Initiatives for HCV Management at the National Level – **Filip Nowak**, President of the National Health Fund (NFZ)
* **12.30 - 12.50**  
  Global Status and Poland's National Elimination Profile for HCV - **Dr. John Ward**, Director, Coalition for Global Hepatitis Elimination
* **12.50 – 13.05**  
  Polish General Practice Screening Status for 2025 – **Representative of Polish Society of Family Medicine**
* **13.05 – 13.15**  
  Cost Effectiveness of Universal HCV Screening Strategies in Poland - **Anna Kowalczuk**, Agency for Health Technology Assessment and Tariff System
* **13.15 – 13.25**  
  Role of the Supreme Medical Chamber in HCV Elimination - **Łukasz Jankowski**, Head of Supreme Medical Chamber in Poland
* **13.25 – 13.40**  
  Decade of Revolutionary HCV Treatment & Importance of Short Treatment Duration – **Prof. Robert Flisiak**

**13.40 – 13.55 Coffee Break**

**13:55 – 15:55 II SESSION: Key Learnings on National Screening Programs in EUROPE**

***Moderator: Prof. Jerzy Jaroszewicz, Prof. Anna Piekarska***

* **13.55 – 14.10**  
  Best Practices from Germany - **Prof. Christoph Sarrazin**, J.W. Goethe University Hospital Frankfurt
* **14.10 – 14.25**  
  Hospital Screening Project in Spain (DECALOG) - **Prof. Maria Butti**, Hospital General Universitario Valle Hebron, Barcelona
* **14.25 – 14.40**  
  Elimination of HCV in Spanish Prisons and PWIDs – **Prof. Rafael Esteban**, Hospital General Universitario Valle Hebron, Barcelona
* **14.40 – 14.55**  
  National HCV Screening Program in Lithuania - **Prof. Limas Kupčinskas**, Lithuanian University of Health
* **14.55 – 15.55**  
  Experts Debate Panel Discussion**:** **Enhancing and Developing Poland's HCV Elimination Program**  
  ***Moderator:******Michał Dobrołowicz***

**Participants** : **Maciej Karaszewski** - Director, Department of Medical Services, Ministry of Health, **Prof. Miłosz Parczewski** – National Consultant, **Beata Małecka-Libera** – Senator, **Anna Kowalczuk** – AOTMiT, **Paweł Grzesiowski** – Chief Sanitary Inspector, **Krzysztof Bojarski** – Member of Parliament, Health Committee, **Wodzisław Giziński** – Member of Parliament, Health Committee, **Prof. Robert Flisiak, Magdalena Władysiuk** - CEESTAHC

**15.55 – 16.10 Coffee Break**

**16:10 – 17:40 III SESSION: Screening Strategy for Integrating HCV as a Multisystemic Disease**

***Moderator: Prof. Małgorzata Pawłowska, Prof. Robert Flisiak***

* **16.10 – 16.25**  
  Oncological Perspectives in HCV Screening - **Prof. Dawid Murawa**
* **16.25 – 16.40**  
  Transplantology's Role in HCV Management - **Prof. Maciej Kosieradzki**
* **16.40 – 17.40**  
  Experts Debate Panel Discussion**:** **Multifaceted Approach to the HCV Virus and Its Impact on Various Fields of Medicine and Public Health  
  Participants** (5 minutes each)

1. **Justyna Mieszalska** – Head of Medical Centre WUM Sp. z o.o.
2. **Konrad Korbiński** – Department of Coordination Oncology Care, MoK
3. **Prof. Dawid Murawa-** Department of Surgery and Oncology, Medical College of the University of Zielona Góra
4. **Bernard Waśko** – NIPH-NIH
5. **Prof. Jolanta Walusiak-Skarupa** – Institute of Occupational Medicine

**17.40 – 17.55 Coffee Break**

**17:55 – 18:55 IV SESSION: Key Learnings on HCV Elimination in Prisons in Europe**

***Moderator:******Prof. Krzysztof Tomasiewicz****,* ***Dr. Anna Bogusławska Marzec****- National AIDS Centre*

* **17.55 – 18.10**  
  Polish Public Health Initiatives - **Dagmara Korbasińska-Chwedczuk**, Department of Public Health, Ministry of Health
* **18.10 – 18.25**  
  Evaluation of Prisoner Projects in the Czech Republic - **Dr. Vratislav Rehak**
* **18.25 – 18.40**  
  Challenges and Achievements in HCV Management in Polish Prisons - **Dr. Anna Brzezińska**
* **18.40 – 18.55** **Discussion**

**18:55 – 20:00 V SESSION: Role of Patient Associations in HCV Elimination**

***Moderator:******Prof. Dorota Zarębska Michaluk****,* ***Magdalena Ankiersztejn-Bartczak***

* **18.55 – 19.05**  
  **Marzanna Bińkowska**  - Patient Rights Ombudsman
* **19.05 – 19.20**  
  Activation of Patient Advocacy in Greece – **George Kalamitsis**, Hellenic Liver Patient Association "Prometheus"
* **19.20 – 19.35**  
  Support and Activities for Refugees in Poland – **Barbara Pepke**, Hope Star Foundation
* **19.35 – 19.50**  
  Non-Medical Testing Approaches in Poland - **Dr. Magda Ankiersztejn Bartczak**, Foundation for Social Education
* **19.50 – 20.00**  
  Online Engagement for Patients in Poland - **Sebastian Gawlik**, Urszula Jaworska Foundation

**20.00** Closing and Summary – **Prof. Krzysztof Tomasiewicz**

**20.30** Gala Dinner (Conference Room Polonia Palace)

**26.04.2025**

**09.00 – 10.10 I SESSION: MASLD and liver diseases diagnostics**

***Moderator: Prof. Michał Kukla, Prof. Marta Wawrzynowicz Syczewska***

* **09.00 - 09.15**

How to optimize HCC surveillance?- **Prof. Jerzy Jaroszewicz**

* **09.15 - 09:30**

Experiences in HCC diagnostics using biomarkers- **asst. prof. Sanja Stanković (Serbia)**

* **09.30-09.45**

Monitoring of liver cirrhosis – what to do to be aware of consequences**- Prof. Marta Wawrzynowicz-Syczewska**

* **09.45-10.00**

Liver biopsy versus/together with non-invasive tests –**Robert Flisiak**

* **10.00-10.10 Discussion**

**10.10 – 10.25 Coffee Break**

**10.25 - 11.35 II SESSION: Rare/not diagnosed liver diseases**

***Moderator: Prof. Jerzy Jaroszewicz, Prof. Anna Piekarska***

* **10.25 - 10.40**

PBC – diagnostic and therapeutic perspective- **Prof. Michał Kukla**

* **10.40-10.55**

HDV – shall we screen all HBV infected patients – **Prof. Dorota Zarębska-Michaluk**

* **10.55-11.10**

HCC – how to avoid and treat – **Prof.** **Marek Pacholczyk**

* **11.10-11.25**

Hepatic encephalopathy – diagnosis and treatment at different stages of disease – **Prof. Anatol Panasiuk**

* **11.25 - 11.35 Discussion**

**11.35 – 11.50 Coffee Break**

**11.50 – 13.10 III SESSION: MASLD**

***Moderator: Dr Andrzej Gietka, Prof. Krzysztof Tomasiewicz***

* **11.50 - 12.05**

New nomenclature of steatosis liver disease – impact on everyday clinical practice – **Prof. Anna Piekarska**

* **12.05 - 12.20**

Risk groups of MASLD and how to screen them **-** **Dr Gabrielė Milaknytė,** Vilnius University Santaros Clinics

* **12.20 - 12.35**

Cardiovascular disease and MASLD – **Prof. Filip Szymański**

* **12.35 - 12.50**

Do we have any treatment for MASH- **Dr n med. Jakub Klapaczyński**

* **12.50 - 13.05**

Future of MASLD specific therapy – **Prof. Krzysztof Tomasiewicz**

* **13.05 - 13.10 Discussion**
* **13.10 - 13.20 C**losing **– Prof. Krzysztof Tomasiewicz**
* **13.20 Lunch and departure**